Table 3.

Plasma ANP and ET concentrations and urinary ET-1 excretion after oral administration of 1, 5, or 10 mg asimadoline as compared with placebo in each group of eight healthy subjects in the absence (0–2 h) and presence of 2.5% saline infusion (2–4 h). #P < 0.01 for effects of 2.5% saline infusion.

Parameter	Collection interval	Placebo	1 mg asimadoline	Placebo	5 mg asimadoline	Placebo	10 mg asimadoline
Plasma ANP concentration
(pmol l−1)
	−2–0 h	9.1 ± 3.7	9.1 ± 1.6	11.7 ± 3.7	10.7 ± 3.7	9.4 ± 2.6	8.5 ± 1.6
	0–2 h	8.8 ± 3.3	8.5 ± 1.6	10.4 ± 3.7	8.8 ± 1.6	9.4 ± 1.6	7.8 ± 2.6
	2–4 h (2.5% NaCl i.v.)	15.9 ± 5.2 #	15.6 ± 4.2 #	15.3 ± 2.6 #	15.9 ± 2.6 #	15.9 ± 4.2 #	16.6 ± 1.6 #
Plasma ET-1 concentration
(pmol l−1)
	−2–0 h	4.5 ± 1.1	3.9 ± 1.2	3.9 ± 1.3	3.4 ± 1.2	4.0 ± 1.3	3.1 ± 1.3
	0–2 h	4.0 ± 1.3	4.2 ± 1.2	4.7 ± 2.4	4.1 ± 1.1	3.7 ± 1.1	3.6 ± 1.3
	2–4 h (2.5% NaCl i.v.)	4.5 ± 1.2	3.9 ± 1.1	4.6 ± 1.4	3.8 ± 0.8	3.2 ± 1.3	3.8 ± 1.4
Urinary ET-1 excretion
(pmol min−1)
	−2–0 h	28.8 ± 19.2	34.8 ± 18.0	30.4 ± 16.0	26.8 ± 11.6	23.2 ± 16.0	17.6 ± 7.6
	0–2 h	23.2 ± 5.2	25.6 ± 6.4	27.6 ± 3.2	33.2 ± 11.6	27.2 ± 5.2	21.7 ± 13.3
	2–4 h (2.5% NaCl i.v.)	39.2 ± 8.4 #	42.8 ± 7.6 #	38.0 ± 9.6 #	37.6 ± 9.6 #	39.6 ± 13.6 #	41.7 ± 17.3 #